161 related articles for article (PubMed ID: 4038749)
21. Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience.
Agrawal C; Bansal S; Biswas M; Gupta M; Nautiyal V; Ahmed M
South Asian J Cancer; 2020 Jul; 9(3):121-125. PubMed ID: 33937132
[No Abstract] [Full Text] [Related]
22. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
[TBL] [Abstract][Full Text] [Related]
23. Safety of same-day administration of gemcitabine plus cisplatin chemotherapy for urothelial carcinoma.
Tsuru I; Niimi F; Honda S; Azuma T
Mol Clin Oncol; 2021 Mar; 14(3):57. PubMed ID: 33604047
[TBL] [Abstract][Full Text] [Related]
24. Long-term trends in sex difference in bladder cancer survival 1975-2009: A population-based study in Osaka, Japan.
Aoe J; Ito Y; Fukui K; Nakayama M; Morishima T; Miyashiro I; Sobue T; Nakayama T
Cancer Med; 2020 Oct; 9(19):7330-7340. PubMed ID: 32794368
[TBL] [Abstract][Full Text] [Related]
25. Molecular and histopathology directed therapy for advanced bladder cancer.
Alifrangis C; McGovern U; Freeman A; Powles T; Linch M
Nat Rev Urol; 2019 Aug; 16(8):465-483. PubMed ID: 31289379
[TBL] [Abstract][Full Text] [Related]
26. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
27. Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Marcq G; Jarry E; Ouzaid I; Hermieu JF; Henon F; Fantoni JC; Xylinas E
Ther Adv Urol; 2019; 11():1756287218823678. PubMed ID: 30728860
[TBL] [Abstract][Full Text] [Related]
28. The continuing role of chemotherapy in the management of advanced urothelial cancer.
Gómez De Liaño A; Duran I
Ther Adv Urol; 2018 Dec; 10(12):455-480. PubMed ID: 30574206
[TBL] [Abstract][Full Text] [Related]
29. A Festschrift in Honor of Edward M. Messing, MD, FACS.
Joseph JV; Brasacchio R; Fung C; Reeder J; Bylund K; Sahasrabudhe D; Yeh SY; Ghazi A; Fultz P; Rubens D; Wu G; Singer E; Schwarz E; Mohile S; Mohler J; Theodorescu D; Lee YF; Okunieff P; McConkey D; Rashid H; Chang C; Fradet Y; Guru K; Kukreja J; Sufrin G; Lotan Y; Bailey H; Noyes K; Schwartz S; Rideout K; Bratslavsky G; Campbell SC; Derweesh I; Abrahamsson PA; Soloway M; Gomella L; Golijanin D; Svatek R; Frye T; Lerner S; Palapattu G; Wilding G; Droller M; Trump D
Bladder Cancer; 2018 Oct; 4(Suppl 1):S1-S43. PubMed ID: 30443561
[No Abstract] [Full Text] [Related]
30. Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer.
Arai S; Hara T; Matsui Y; Koido K; Hashimoto H; Shinoda Y; Komiyama M; Fujimoto H; Terakado H
Case Rep Oncol; 2018; 11(2):450-460. PubMed ID: 30079018
[TBL] [Abstract][Full Text] [Related]
31. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
32. Brain metastasis from renal urothelial carcinoma successfully treated by metastasectomy.
Fang WK; Jou YC; Dai YC; Ko PC; Huang YF
Ci Ji Yi Xue Za Zhi; 2018; 30(1):41-43. PubMed ID: 29643716
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
34. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.
Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
Mol Clin Oncol; 2017 Dec; 7(6):1112-1118. PubMed ID: 29285384
[TBL] [Abstract][Full Text] [Related]
35. [Chemotherapy: from bacteria killer to antitumor agent : A striking transformation in the term over the last century].
Konert J
Urologe A; 2017 Nov; 56(11):1455-1460. PubMed ID: 28821902
[TBL] [Abstract][Full Text] [Related]
36. Landmarks in the treatment of muscle-invasive bladder cancer.
Lobo N; Mount C; Omar K; Nair R; Thurairaja R; Khan MS
Nat Rev Urol; 2017 Sep; 14(9):565-574. PubMed ID: 28675174
[TBL] [Abstract][Full Text] [Related]
37. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.
Miyata Y; Mitsunari K; Akihiro A; Watanabe SI; Matsuo T; Ohba K; Sakai H
Oncol Lett; 2017 Feb; 13(2):811-818. PubMed ID: 28356963
[TBL] [Abstract][Full Text] [Related]
38. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
39. Outcome of urinary bladder cancer after combined therapies.
Anghel RM; Gales LN; Trifanescu OG
J Med Life; 2016; 9(1):95-100. PubMed ID: 27974922
[No Abstract] [Full Text] [Related]
40. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Funt SA; Rosenberg JE
Nat Rev Clin Oncol; 2017 Apr; 14(4):221-234. PubMed ID: 27874062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
